Abstract: An LED fabrication method includes forming impurity release holes by focusing a laser at the substrate back surface, and forming invisible explosion points by focusing a laser inside the substrate on positions corresponding to the impurity release holes; communicating the impurity release holes with the invisible explosion points to release impurities generated during forming of the invisible explosion points from the substrate through the impurity release holes, thereby avoiding low external quantum efficiency resulting from adherence of impurities to the side wall of the invisible explosion points. By focusing on a position with 10 ?m˜40 ˜m inward from the substrate back side, adjusting laser energy and frequency to burn holes inside the substrate to penetrate and expose the substrate back surface, thereby effectively removing by-products, and reducing light absorption by such by-products, light extraction from a side wall of the LED can also be improved and light extraction efficiency is enhanced.

Abstract: Sulfide stress cracking of a metal component may be inhibited by treating the metal component with a mixture comprising at least one organic aldehyde and at least one surfactant. Such metal components may be those suitable for use in a downhole environment, at a well site, in a storage facility, in a transportation infrastructure, in a refinery facility, and any combination thereof where the metal component may be exposed to hydrogen sulfide.

Abstract: This document provides methods and materials for generating GABAergic neurons in brains. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide and nucleic acid encoding a Dlx2 polypeptide to trigger glial cells (e.g., NG2 glial cells or astrocytes) within the brain (e.g., striatum) into forming GABAergic neurons (e.g., neurons resembling medium spiny neurons such as DARPP32-positive GABAergic neurons) that are functionally integrated into the brain of a living mammal (e.g., a human) are provided.

Abstract: A semiconductor device is disclosed that comprises a first non-volatile memory cell, a second non-volatile memory cell, an active region between the first and second memory cells, and an electrically conductive contact touching the active region, wherein the contact has a horizontal cross-section that is at least five percent smaller in a first dimension than in a second dimension.

Abstract: Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-?), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and ?-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG, purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.

Abstract: Manufacturing of semiconductor devices often involves performed photolithography to pattern and etch the various features of those devices. Such photolithography involves masking and focusing light onto a surface of the semiconductor device for exposing and etching the features of the semiconductor devices. However, due to design specifications and other causes, the semiconductor devices may not have a perfectly flat light-incident surface. Rather, some areas of the semiconductor device may be raised or lowered relative to other areas of the semiconductor device. Therefore, focusing the light on one area causes another to become unfocused. By carefully designing a photomask to cause phase shifts of the light transmitted therethrough, focus across all areas of the semiconductor device can be achieved during photolithography, which results in sharp and accurate patterns formed on the semiconductor device.

Abstract: Disclosed herein is a semiconductor device including a first dielectric disposed over a channel region of a transistor formed in a substrate and a gate disposed over the first dielectric. The semiconductor device further includes a second dielectric disposed vertically, substantially perpendicular to the substrate, at an edge of the gate, and a spacer disposed proximate to the second dielectric. The spacer includes a cross-section with a perimeter that includes a top curved portion and a vertical portion that is substantially perpendicular to the substrate. Further, disclosed herein, are methods associated with the fabrication of the aforementioned semiconductor device.

Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with an MDM2 antagonist of formulae I, II and III as disclosed herein, said method comprising a multivariate analysis comprising detecting relative amounts of certain MDM2 protein expressing cells and, optionally additional co-variates selected from a gene signature as disclosed herein, p53 mutation status, the patient's age and ECOG score at baseline as a biomarker for predicting said patient's response to treatment.

Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.

Abstract: This invention relates to a gradient amplifier system for driving a gradient coil and a configuration method thereof. The gradient amplifier system comprises a gradient amplifier for driving a gradient current through the gradient coil, wherein the gradient amplifier further comprises a gradient filter; a controller coupled to the gradient amplifier for controlling the gradient current in the gradient coil; a feedback loop for feeding only the gradient current in the gradient coil back to the controller, wherein the controller is configured based on only the fedback gradient current in the gradient coil, and wherein filter parameters of the gradient filter are adjusted to achieve a minimum shift between predetermined poles representing a desired performance of the gradient amplifier system (21) and actual poles of a rational transfer function associated with the controller.

Abstract: The present disclosure provides protein-enriched, tobacco-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one tobacco material (e.g., a particulate tobacco material or a tobacco-derived extract), at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol.

Abstract: The present disclosure provides protein-enriched, nicotine-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one nicotinic compound, at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol.

Abstract: Provided are compositions, articles and methods that relate to promoting neurogenesis or neuroregeneration in mammalian nervous system. Embodiments relate to use of groups of compounds that contain Crizotinib (Cri), Flurbiprofen, Lithium Chloride (Li), Vitamin C (VC), Ceritinib (Cer) or Pirfenidone (PFD). In certain implementations glial cells are converted into functional neurons.

Abstract: The invention provides a method, composition, and system for inhibiting the corrosion of metal that is exposed to aqueous acid, where the composition comprises a thietane compound, a thiirane compound, or a combination thereof.

Abstract: Use of at least an MDM2 gene panel, preferably a four gene MDM2 gene panel, as a biomarker for predicting the response to a MDM2 antagonist.

Abstract: A patterned sapphire substrate has a first surface and a second surface opposite to each other; the connection zone between first protrusion portions has no C surface (i.e. (0001) surface); and the patterned sapphire substrate may have no C surface on the growth surface to reduce the threading dislocation density of the GaN epitaxial material on the sapphire substrate.

Abstract: The invention provides a method, composition, and system for inhibiting sulfide stress cracking of metal that is exposed to aqueous sulfide and aqueous acid, and optionally brine, where the composition comprises a thietane compound, a thiirane compound, or a combination thereof.

Abstract: A trans-resveratrol selenide for treating cancer has such a structure as: wherein hydroxyls at position 3, 4 and 5 are replaceable, at least one hydroxyl at position 3, 4, 5 is replaced with R, R is alkali metal ion and selenium coordination complex, and The trans-resveratrol selenide preparation is able to treat various cancers, such as lung cancer, lymphoma, stomach cancer, liver cancer, small intestine cancer, colorectal cancer and gynecologic cancer, and has a good curative effect.

Abstract: A method is provided for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or for determining the continuation of GPC3-targeting drug therapy for a patient treated with GPC3-targeting therapy. The method includes determining the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of the immunocyte or the expression level of the molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. GPC3-targeting drugs and drug preparations for use according to the disclosed methods are also provided.

Abstract: The invention provides a method, composition, and system for inhibiting sulfide stress cracking of metal that is exposed to aqueous sulfide and aqueous acid, and optionally brine, where the composition comprises a thietane compound, a thiirane compound, or a combination thereof.